Pregnancy outcome after treatment with the ergot derivative, cabergoline

被引:100
作者
Robert, E
Musatti, L
Piscitelli, G
Ferrari, CI
机构
[1] FATEBENEFRATELLI HOSP,ENDOCRINOL UNIT,MILAN,ITALY
[2] PHARMACIA & UPJOHN,R&D,MILAN,ITALY
关键词
pregnancy; cabergoline;
D O I
10.1016/0890-6238(96)00063-9
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The goal of this article is to assess the reproductive safety of cabergoline, a new ergot derivative proposed in hyperprolactinemic disorders, Investigated in different animal species, the drug showed no teratogenic or embryotoxic effects on rabbits, Considering the dose envisaged for humans, large safety margins exist. Our sample consists of 226 pregnancies occurring in 205 women, Follow-up is available for 204. There were 24 miscarriages and three abortions induced because of major malformations (one Down syndrome in a 42-year-old woman, one limb-body wall complex, one hydrocephalus), Two of the 148 single liveborn infants had significant malformations: one megaureter, one scaphocephaly, This series shows no increase in miscarriage rate, a distribution of birthweights and sex ratio within the expected range, and no increased rate of congenital malformations, Follow-up of babies, limited to 107 cases, thus far indicates normal physical and mental development.
引用
收藏
页码:333 / 337
页数:5
相关论文
共 17 条
  • [1] BELTRAME D, UNPUB REPROD TOXICOL
  • [2] EFFECTIVENESS AND TOLERABILITY OF LONG-TERM TREATMENT WITH CABERGOLINE, A NEW LONG-LASTING ERGOLINE DERIVATIVE, IN HYPERPROLACTINEMIC PATIENTS
    CICCARELLI, E
    GIUSTI, M
    MIOLA, C
    POTENZONI, F
    SGHEDONI, D
    CAMANNI, F
    GIORDANO, G
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 69 (04) : 725 - 728
  • [3] CABERGOLINE IN THE LONG-TERM THERAPY OF HYPERPROLACTINEMIC DISORDERS
    FERRARI, C
    PARACCHI, A
    MATTEI, AM
    DEVINCENTIIS, S
    DALBERTON, A
    CROSIGNANI, P
    [J]. ACTA ENDOCRINOLOGICA, 1992, 126 (06): : 489 - 494
  • [4] FERRARI C, 1995, HUMAN REPROD, V10, P101
  • [5] GROTTOLI S, 1991, J ENDOCRINOL INVE S1, V14, P104
  • [6] HAMMERSLOUGH CR, 1992, PUBLIC HEALTH REP, V107, P269
  • [7] CABERGOLINE TREATED HYPERPROLACTINEMIA RESULTS IN PREGNANCY IN A BROMOCRIPTINE INTOLERANT PATIENT AFTER 17 YEARS OF INFERTILITY
    JONES, TH
    FRASER, RB
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1994, 101 (04): : 349 - 350
  • [8] Kallen, 1988, EPIDEMIOLOGY HUMAN R
  • [9] BROMOCRIPTINE IN PREGNANCY - SAFETY ASPECTS
    KRUPP, P
    MONKA, C
    [J]. KLINISCHE WOCHENSCHRIFT, 1987, 65 (17): : 823 - 827
  • [10] LAFERLA JJ, 1986, CLIN OBSTET GYNAECOL, V13, P105